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usually leaves patients with no treatment options. Autolo-
gous bone marrow cells may have potential to reduce the
instances of amputation and improve quality of life for these
patients.
Methods: 49 patients with thromboangitis obliterans
resulting in CLI were treated with a composition of con-
centrated bone marrow nucleated cells. A total of 240 mL
of aspirate was processed using a point of care centrifuge
(Harvest Technologies, Plymouth, MA) to yield 40 mL of
treating volume. The patients were divided equally into two
treatment groups. Group 1 received forty 1 mL direct
intramuscular injections in the ischemic regions below the
knee and Group 2 received twenty 1 mL direct intramus-
cular injections below the knee and an intra-arterial infu-
sion of 20 mL down the SFA into the lower leg. An
evaluation of these patients was conducted at 12 and 26
weeks.
Results: All patients enrolled were men with the fol-
lowing demographics: mean age 44.9, all smokers. There
were six adverse events in each treatment group. None were
considered to be related to the biologic treatment. No
patients died. Limb salvage was 87.5% and all major end-
points showed statistically significant improvement over
baseline: Quality of Life assessment (Rand-36 question-
naire) p0.0009; perception of pain p0.0001; TcPO2
and ABI measurement p0.0001 & p 0.0003 respec-
tively. There was 100% reduction in pain medications.
Mean number of nucleated cells delivered 3.63x10. The
delivery method showed no statistical difference.
Conclusions: Based on these results, this bone marrow
composition may be considered safe and has shown poten-
tial to reduce amputation rates. This study has also shown
that both the methods of delivery are equally effective and
safe.
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Congestive Heart Failure with Systolic Dysfunction Is
Associated with Decreased Patency after Endovascular
Intervention for Symptomatic Peripheral Arterial Dis-
ease
Andrew J. Meltzer, Kathy A. Gallagher, Sikandar Z. Khan,
Peter Connolly, Francesco A. Aiello, In-Kyong Kim, Gau-
tam Shrikhande, Asad Kahn, James F. McKinsey. Vascular
Surgery, New York-Presbyterian Hospital, New York, NY
Objectives: Congestive heart failure (CHF) predicts
morbidity and mortality after treatment of peripheral arte-
rial disease. The impact on procedural success, however,
remains unknown. We hypothesized that CHF with re-
duced left ventricular ejection fraction (LVEF) results in a
diminished perfusion pressure and a low-flow state that
could predispose arterial interventions to fail.
Methods: A prospective database identified patients
with CHF who underwent endovascular arterial interven-
tion from 2004-2009. Demographics, co-morbidities, in-
tervention, LVEF, and outcomes were recorded. Patients
were followed clinically and by duplex ultrasound. Kaplan-
Meier survival analysis and Cox Regression were used.
Results: Of 1220 patients undergoing intervention,
271 patients (22%) with documented CHF underwent
intervention for claudication (23%) or critical limb ischemia
(CLI) (77%). Primary patency at 1 year was 51.92.5%
among those with CHF, compared to 64.61.3% in con-
trols (p0.001). In the setting of CHF, 1 year patency was
56.64.1% if LVEF40% vs 43.23.5% if LVEF40%
(p0.001). (Table 1). Among those with CLI, limb sal-
vage rates were equivalent between controls and patients
with CHF and LVEF40%, but worse with LVEF40%
(p0.01) and LVEF20% (p0.001).
Conclusions: CHF is an independent risk factor for
failure of endovascular intervention. Specifically, low LVEF
(40%) predicts loss of patency. The inverse association
between patency and LVEF needs further assessment.







Control 64.6  1.3 53.1  1.4 47.5  1.6
CHF 51.9  2.5 42.8  2.7 38.5  2.8
LVEF40% 56.6  4.1 45.9  4.4 36.0  4.8
LVEF40% 43.2  3.5 26.9  3.7 16.8  4.9
P-Values
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Video Presentation
Endovascular Management of an Aorto-Iliac Occlusion
Utilizing an IVUS Guided Re-entry Device
Ali Amin. Surgery, Reading Hospital and Medical Center,
Reading, PA
Background: 43 yr old female. pain bilateral lower
extremity for 8 months. Pain worse right side, can only
walk few feet. pain at night, chronic numbness right foot.
Hypertension, COPD, HIV smoker Absent femoral/
pedal pulses. ABI right .36 left .64 Abdominal duplex:
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occlusion distal aorta-bilateral common iliac artery oc-
clusion. Patent distal external iliac/common femoral.
Technical Description: Left brachial access with
miro-puncture. 4 Fr. Sheath, pig tail catheter inserted to
abdominal aorta. Arteriogram showed distal aortic oc-
clusion extending to bilateral common iliac arteries with
reconstitution of external iliac. Under road mapping
sheath placed bilateral common femoral arteries. Right
CFA 5 Fr. Sheath, left CFA 6 Fr. Sheath. Selective
arteriogram through right sheath, showed more exten-
sive disease of right iliac and proximal external iliac artery
compared to the left side.Using a .035 hydrophilic wire
with a 4 Fr. Vertebral catheter used to cross right iliac
occlusion. Patent aortic distal lumen entered using wire
and catheter techniques. Left side, same technique used
cross common iliac artery occlusion, but aortic true
lumen could not be entered. .035 wire exchanged for
.014 wire. Pioneer Catheter (Re-entry device with IVUS
tip) inserted through left Sheath to reconstitution point.
Using IVUS, true lumen was identified with blood flow
on top. Needle from Pioneer catheter advanced, under
fluoroscopy, .014 wire passed into aorta. By measuring
depth of penetration on IVUS, needle length can be
adjusted on the Pioneer to penetrate through occlusion.
Needle retracted and Pioneer removed. A .035 catheter
inserted over .014 wire and wire exchanged for .035
wire. Patient given IV heparin and bilateral iliac angio-
plasty/ stenting performed. Stenting done using self-
expandable stents. no pressure gradient, Patient toler-
ated procedure without complications, discharge next
day. Office follow up, had palpable bilateral femoral
pulses with ABIs of .80 and .90. Her pain, completely
resolved.
Author Disclosures: A. Amin: Medtronic, Consulting fees
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Preoperative Vein Mapping Reduces Major Surgical
Site Infections (SSI) and Readmissions in Infrainguinal
Bypass Surgery: Results of a Prospective Randomized
Trial
Klaus Linni, Nina Mader, Manuela Aspalter, Enzo But-
turini, Ara Ugurluoglu, Wolfgang Hitzl, Thomas J. Hol-
zenbein. Department of Vascular and Endovascular Sur-
gery, PMU Salzburg, Salzburg, Austria
Objectives: Although duplex vein mapping (DVM) of
the greater saphenous vein (GSV) is common practice,
there is no level-1 evidence for its application. The aim of
our prospective randomized trial was to study the impact of
preoperative DVM in infrainguinal bypass surgery.
Methods: Consecutive patients undergoing primary
bypass were prospectively randomized for DVM of the
GSV (Group A) or not (Group B) before surgery. SVS
reporting standards were applied.
Results: From 12/2009 to 12/2010 103 patients were
enrolled into the study. Group A (n 51) underwent DVM
of the GSV, Group B (n  52) did not. There was no
statistically significant difference between both groups regard-
ing age (A: 72.8 vs B: 71.1), gender (females: A: 29.4% vs B:
34.6%), cardiovascular risk factors, body mass index (A: 25.9
vs B: 26.1), bypass anatomy and runoff. Both groups were
equal regarding operative time (A: 151.4 min. vs B: 151.1
min), incisional length (A: 39.4cm vs B: 39.9cm), secondary
bypass patency at 30 days (A: 96.1% vs B: 96.2%, p n.s.). In
Group B there were 6 intraoperative changes of the operative
plan vs none in Group A (p 0.014), always due to conduit
issues. Median postoperative length of stay was longer in
Group B as compared to Group A (p  n.s.). SSI were
classified according to literature into minor (A: 23.5% vs B:
23.1% p n.s.) and major (A: 1.9% vs B: 21.2% p 0.004).
Readmissions due to SSI: Group A: 3.9% vs Group B: 19.2%
(p 0.038). In Group B two patients died following compli-
cations of SSI. Multivariate analysis identified preoperative
DVM as the only significant factor influencing the develop-
ment of major SSI (p0.038).
Conclusions: Routine DVM should be recommended
for infrainguinal bypass surgery. According to our study
preoperative DVM significantly avoids unnecessary surgical
exploration, development of major SSI, as well as frequency
of readmissions for SSI treatment.
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Outcomes Following Heparin-Induced Thrombocyto-
penia in Patients with Heparin Bonded Vascular Grafts
Karthikeshwar Kasirajan. Emory University, Atlanta, GA
Objectives: Heparin-induced thrombocytopenia (HIT)
can result in a life or limb threatening condition. This study
was to evaluate the outcomes of patients with implanted
Gore propaten Vascular Grafts (W.L. Gore, Flagstaff, AZ)
and a subsequent suspicion of HIT.
Methods: All reports of suspected HIT following im-
plant of the propaten vascular graft reported to W.L. Gore
were analyzed.
Results: Overall, as of December 2010, there have been
24 cases of suspected HIT following implant for lower ex-
tremity revascularization (13), dialysis (5), extra-anatomical
(2), or other sites (4).HITwas confirmedby of ormore of the
these tests; ELISA, HIPA, SRA, or a HIT Panel. Among
patients with available data points, the mean pre-operative
heparin dose was 5071  1835 units and 4 patients had
post-operative heparin infusion. Mean pre-op platelet
count was 253,714  66,354 and dropped post-op to
56,769  38,745. Platelet counts returned to normal
following discontinuation of systemic heparin. Grafts
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